BIIB and IONS Related Headlines
Go Back- Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
- BIOGEN publishes study results for high-dose nusinersen in Nature Medicine
- Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
- BIOGEN receives EU approval for high dose SPINRAZA for spinal muscular atrophy
- Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
- Biogen (BIIB): High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
- High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
- Biogen completes acquisition of Alcyone Therapeutics
- Biogen Completes Acquisition of Alcyone Therapeutics
- Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
- FDA requests technical updates for Biogen's high dose nusinersen application
- Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
- Biogen to acquire Alcyone Therapeutics for $85 million upfront
- Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
- New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
- Biogen (BIIB) to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
- Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB and IONS Related Press Releases
Go Back- Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
- Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
- Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
- High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
- Biogen Completes Acquisition of Alcyone Therapeutics
- Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
- Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
- New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
- Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
